Please check your internet connection and try again.
# Aztreonam-Avibactam (Emblaveo)
## Overview
Aztreonam-avibactam is a fixed-dose combination of a monobactam antibiotic and a non-beta-lactam beta-lactamase inhibitor. It is designed to overcome resistance mediated by metallo-beta-lactamases (MBLs), such as NDM, VIM, and IMP, as well as serine-beta-lactamases (ESBLs, AmpC, KPC).
*Note: In the US, this combination is currently investigational or available via Expanded Access; generic Aztreonam remains the standard monobactam.*
## Primary Indications
Treatment of complicated intra-abdominal infections (cIAI), complicated urinary tract infections (cUTI, including pyelonephritis), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP) caused by aerobic Gram-negative organisms where other options are limited or ineffective.
## Adult Dosing
* **Standard Regimen:** 500 mg (aztreonam) / 137.5 mg (avibactam) administered intravenously every 8 hours.
* **Infusion Time:** Administer as a 2-hour intravenous infusion.
## Pediatric Dosing
Safety and efficacy have not been fully established in pediatric populations. Dosing should be determined strictly by institutional infectious disease specialists or clinical trials/compassionate use protocols.
## Dose Adjustments
* **Renal Impairment:** Requires significant dose adjustment based on CrCl (mL/min). Decreased frequency or reduced doses are necessary once CrCl falls below 50 mL/min.
* **Hepatic Impairment:** No dosage adjustment typically required.
* **Renal Replacement Therapy:** Significant clearance occurs during hemodialysis; supplemental dosing or post-dialysis timing is typically required. Consult specific institutional protocols.
## Contraindications
* Known hypersensitivity to aztreonam or avibactam.
* Severe hypersensitivity (e.g., anaphylaxis) to any other beta-lactam antibiotic.
## Adverse Effects
* **Common:** Diarrhea, nausea, vomiting, dizziness.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), hypersensitivity reactions (including rash or anaphylaxis), and potential for elevated liver enzymes.
## Key Drug Interactions
* **Probenecid:** May increase serum concentrations of aztreonam by inhibiting renal tubular secretion.
* **Beta-lactams:** Generally avoided concomitantly, though this agent is specifically selected for unique spectrum coverage.
## Monitoring
* **Renal Function:** Monitor SCr and CrCl regularly for dose titration.
* **Clinical Response:** Monitor for resolution of site-specific infection.
* **Safety:** Monitor for signs of *C. difficile* infection and allergic hypersensitivity.
## Clinical Pearls
* Aztreonam-avibactam is highly stable against MBL-producing organisms that hydrolyze carbapenems.
* Unlike other beta-lactam/beta-lactamase inhibitor combinations, aztreonam does not cross-react with most cross-reactive penicillin or cephalosporin allergies, theoretically making it safer for patients with severe beta-lactam allergies.
* Ensure adequate specimen collection for susceptibility testing before initiation, if possible.
***
**Educational Disclaimer:** This information is for educational purposes only. Dosing and clinical application must be verified against current institutional protocols, official package inserts, and local susceptibility data. Always consult a clinical pharmacist or infectious disease specialist when prescribing specialized antimicrobial combinations.
